Mesoblast limited (ASX: MSB) has been one of the standout performers on the ASX over the past three months. The company’s share price dropped as low as $1.02 on 23 March amid the economic fallout from the coronavirus pandemic.
Since then, however, the Mesoblast share price has really soared and is currently trading at $4.18. That’s a massive 310% growth in the company’s share price in just three months. This includes a 4.5% increase so far today.
Mesoblast has become a world leader in developing allogeneic, off-the-shelf, cellular medicines. The ASX listed biotech has successfully leveraged its proprietary cell therapy technology to establish a range of commercial products and late-stage product candidates.
So, what is behind this strong recent rally in the Mesoblast share price?
Helping win the fight against coronavirus
It’s pretty likely that the recent rise of the Mesoblast share price is linked to some promising progress the company is making with its treatment for COVID-19 patients.
In early May, Mesoblast commenced Phase 2/3 trials in the United States of its remestemcel-L treatment. The trials encompassed patients with moderate to severe coronavirus symptoms who required ventilator support.
The trial achieved an 83% survival rate and reported that 75% of patients managed to come off ventilator support within a ten day period. The remestemcel-L product works by counteracting the inflammatory process in the lungs caused by COVID-19. These initial encouraging results were first revealed back in late April at a New York hospital.
Further encouraging results were revealed at the end of May. Phase 2 trial results concluded that remestemcel-L, given in four monthly intravenous doses, significantly improved the outcome for patients with inflammatory lung disease, such as that suffered by COVID-19 patients.
Strong financial performance
Mesoblast’s recent financial performance has also been strong.
The company recorded an 113% increase in overall revenues to US$31.5 million for the first 9 months of FY 2020, compared to the prior corresponding period.
Mesoblast also recorded a 127% increase from milestone revenues involving strategic partnerships.
Where to now for the Mesoblast share price?
With the Mesoblast share price rising by over 300% in the last few months, only time will tell if it can continue this strong performance moving forward. Judging by today’s price, the market is likely expecting further promising clinical trial results to come from this dual listed biotech.
For more exciting growth shares like Mesoblast, check out the following report.
One trick to potentially generating life-changing wealth from the stock market is to buy early-stage growth companies when their share prices still look dirt cheap.
Motley Fool’s resident tech stock expert Dr. Anirban Mahanti has identified 5 stocks he thinks are screaming buys. And you can buy them now for less than $5 a share!
*Extreme Opportunities returns as of June 5th 2020
More reading
- Why A2 Milk, Afterpay, Mesoblast, and Temple & Webster are pushing higher
- Why Zip Co and these All Ords shares have doubled in 12 months
- ASX 200 down 2.2%: Westpac tumbles, TPG reveals special dividend plans
- S&P quarterly rebalance: A2 Milk added to ASX 50 & NEXTDC in the ASX 100
- Here are all the ASX 200 companies that announced capital raisings in May
Motley Fool contributor Phil Harpur has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Why the Mesoblast share price has soared 310% in the last 3 months appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/30Wr7TV
Leave a Reply